NVO (NYSE) - Novo Nordisk A/S
Exchange: USA Stocks • Country: USA • Currency: USD • Type: Common Stock • ISIN: US6701002056
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark. Web URL: https://www.novonordisk.com
Drawdown (Underwater) Chart
External Links for NVO (NYSE) - Novo Nordisk A/S
Warnings
- Uncommon Growth Rate
| Market Cap. | 373,997m USD |
| Enterprise Value | 399,515m USD (+6%) |
| GiC Sector | Health Care |
| GiC Group | Pharmaceuticals, Biotechnology & Life Sciences |
| GiC Industry | Pharmaceuticals |
| GiC SubIndustry | Pharmaceuticals |
| TER | 0.00% |
| IPO / Inception | 1982-01-04 |
Ratings
| Fundamental | 9.07 |
| Dividend | 7.49 |
| Technical | 9.24 |
| Performance | 5.18 |
| Analysts | 3.75 |
| Price / Fair Price TR | 0.91 |
| Price / Fair Price DCF | todo |
Technical
| Growth TTM | 54.93% |
| CAGR 5y | 30.79% |
| CAGR / Mean Drawdown 5y | 5.86 |
| Sharpe Ratio TTM | 1.74 |
| Alpha vs SP500 TTM | 51.28 |
| Beta vs SP500 5y weekly | 0.68 |
| Volatility GJR Garch 1y | 28.31% |
| CAPM | 8.31% |
| Correlation TTM | 0.69 |
| Max Drawdown 5y | 24% |
| Mean Drawdown 5y | 5.3% |
| Price / SMA 200 days | -19.48% |
| Current Volume | 962.4k |
| Average Volume | 1451.8k |
Dividends
| Rate TTM | 1.76 |
| Yield TTM | 1.08% |
| Div. CAGR 5y | 7.81% |
| Consistency of Dividends all time | 96.5% |